41 results
Vasculitis Management - ACR/VF 2021 Guidelines for Treatment & Management
 • Giant Cell Arteritis (GCA)
 •
- ACR/VF 2021 Guidelines ... for Treatment & ... Vasculitis #Management #Treatment ... #ACR2021 #Guidelines ... #algorithm #rheumatology
2021 ACR/VF Guidelines for Management of Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

#Granulomatosis #Polyangiitis #GPA
2021 ACR/VF Guidelines ... and Microscopic Polyangiitis ... Granulomatosis #Polyangiitis ... ACR2021 #Management #rheumatology ... #algorithm #vasculitis
Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021
Vasculitis Management Algorithm ... - ACR/VF 2021 Guidelines ... Vasculitis #Management #Treatment ... #ACR2021 #Guidelines ... #algorithm #rheumatology
2021 ACR/VF Guidelines for Management of Eosinophilic Granulomatosis with Polyangiitis (EGPA)

#EGPA #Eosinophilic #Granulomatosis #Polyangiitis #ACR2021 #Management
2021 ACR/VF Guidelines ... Granulomatosis with Polyangiitis ... Granulomatosis #Polyangiitis ... ACR2021 #Management #rheumatology ... #algorithm #vasculitis
Eosinophilic Granulomatosis with Polyangiitis (EGPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Active
Granulomatosis with Polyangiitis ... - ACR/VF 2021 Guidelines ... Vasculitis #Management #Treatment ... #ACR2021 #Guidelines ... #algorithm #rheumatology
Rheumatoid Arthritis - ACR 2021 Guidelines
 - Low Disease Activity
 - Moderate to High Disease Activity
Arthritis - ACR 2021 Guidelines ... - Low Disease ... Moderate to High Disease ... #management #treatment ... #rheumatology
Autoantibodies and their Disease Associations
ANA - Non-specific; common in SLE, autoimmune hepatitis
Anti-CCP, Rheumatoid factor - RA
Anti-dsDNA
Non-specific; common in SLE ... RA Anti-dsDNA - SLE ... - Drug-induced SLE ... Microscopic polyangiitis ... diagnosis #table #rheumatology
Polyarteritis Nodosa (PAN) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Severe Disease → Remission
- ACR/VF 2021 Guidelines ... • Severe Disease ... • Non-Severe Disease ... Vasculitis #Management #Treatment ... #algorithm #rheumatology
ANA (Antinuclear Antibody) and ANCA (Antineutrophil cytoplasmic antibodies)
 • Systemic lupus erythematosus
   1. Anti-dsDNA
in drug-induced SLE ... connective tissue disease ... 90% • Anti-GBM disease ... antibodies #diagnosis #rheumatology ... #diseases
Systemic Lupus Erythematosus - Summary
Antinuclear (ANA) - 95% - Initial screening test
Anti-dsDNA - 50%
 • Associated
dysmotility • MCTD (SLE ... • Specific for SLE ... Treatment: • ... Erythematosus #SLE ... Summary #diagnosis #rheumatology